132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107
(215) 955-9077
(215) 955-5681 fax
1170 Main Building
Philadelphia, PA 19107
(215) 955-9077
(215) 955-5681 fax
Most Recent Peer-reviewed Publications
- Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract
- Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome
- Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients
- Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis
- Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
- Healthy volunteer registries and ethical research principles
- The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
- Prevalence of obstructive lung disease in HIV population: A cross sectional study
- The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin
- Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient
- The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis
- Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
- The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis
- Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome
- Obstructive sleep apnea syndrome and postoperative complications: Clinical use of the STOP-BANG questionnaire
- Pharmacokinetic evaluation of fosaprepitant dimeglumine
- Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects
- Experimental therapeutics: A paradigm for personalized medicine
- Clinical pharmacology: A paradigm for individualized medicine
- Acid peptic diseases: Pharmacological approach to treatment